Consultants in Neurology, Ltd.

Northbrook, Illinois 60062

0 studies enrolling now · 27 studies all time

What they study most

ADHD, Alzheimer's Disease, Attention Deficit/Hyperactivity Disorder, Autoimmune Diseases of the Nervous System, Brain Atrophy, Clinically Isolated Syndrome, Disease Progression, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, NMO Spectrum Disorder (NMOSD), Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorder

Studies at this site

• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease — Running, not enrolling
• Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis — Running, not enrolling
• A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) — Completed
• Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis — Status unconfirmed
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
• A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis — Status unconfirmed
• Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) — Completed
• Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) — Stopped early
• Tanezumab and Nerve Function In Arthritis Patients — Stopped early
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) — Completed
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis — Completed
• Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — NO_LONGER_AVAILABLE
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis — Completed
• Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients — Completed
• Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter) — Completed
• Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis — Stopped early
• Study of Fampridine-SR Tablets in Multiple Sclerosis Patients — Completed
• A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed
• Autologous T Cell Vaccine (TCV) for Multiple Sclerosis — Completed
• Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis — Completed
• Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD — Completed
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial — Completed
• A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose — Completed